Home > Publications Database > Priorities for research on neuromodulatory subcortical systems in Alzheimer's disease: Position paper from the NSS PIA of ISTAART. > print

001     194973
005     20240306115250.0
024 7 _ |a pmc:PMC10182252
|2 pmc
024 7 _ |a 10.1002/alz.12937
|2 doi
024 7 _ |a pmid:36642985
|2 pmid
024 7 _ |a 1552-5260
|2 ISSN
024 7 _ |a 1552-5279
|2 ISSN
024 7 _ |a altmetric:141358327
|2 altmetric
037 _ _ |a DZNE-2023-00160
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Ehrenberg, Alexander J
|b 0
245 _ _ |a Priorities for research on neuromodulatory subcortical systems in Alzheimer's disease: Position paper from the NSS PIA of ISTAART.
260 _ _ |a Hoboken, NJ
|c 2023
|b Wiley
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1709646971_29111
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The neuromodulatory subcortical system (NSS) nuclei are critical hubs for survival, hedonic tone, and homeostasis. Tau-associated NSS degeneration occurs early in Alzheimer's disease (AD) pathogenesis, long before the emergence of pathognomonic memory dysfunction and cortical lesions. Accumulating evidence supports the role of NSS dysfunction and degeneration in the behavioral and neuropsychiatric manifestations featured early in AD. Experimental studies even suggest that AD-associated NSS degeneration drives brain neuroinflammatory status and contributes to disease progression, including the exacerbation of cortical lesions. Given the important pathophysiologic and etiologic roles that involve the NSS in early AD stages, there is an urgent need to expand our understanding of the mechanisms underlying NSS vulnerability and more precisely detail the clinical progression of NSS changes in AD. Here, the NSS Professional Interest Area of the International Society to Advance Alzheimer's Research and Treatment highlights knowledge gaps about NSS within AD and provides recommendations for priorities specific to clinical research, biomarker development, modeling, and intervention. HIGHLIGHTS: Neuromodulatory nuclei degenerate in early Alzheimer's disease pathological stages. Alzheimer's pathophysiology is exacerbated by neuromodulatory nuclei degeneration. Neuromodulatory nuclei degeneration drives neuropsychiatric symptoms in dementia. Biomarkers of neuromodulatory integrity would be value-creating for dementia care. Neuromodulatory nuclei present strategic prospects for disease-modifying therapies.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Biomarkers
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Alzheimer Disease: pathology
|2 MeSH
650 _ 2 |a Brain: pathology
|2 MeSH
650 _ 2 |a Biomarkers
|2 MeSH
650 _ 2 |a Disease Progression
|2 MeSH
700 1 _ |a Kelberman, Michael A
|b 1
700 1 _ |a Liu, Kathy Y
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Dahl, Martin J
|b 3
700 1 _ |a Weinshenker, David
|b 4
700 1 _ |a Falgàs, Neus
|b 5
700 1 _ |a Dutt, Shubir
|b 6
700 1 _ |a Mather, Mara
|b 7
700 1 _ |a Ludwig, Mareike
|0 P:(DE-2719)9002575
|b 8
|u dzne
700 1 _ |a Betts, Matthew J
|0 P:(DE-2719)2810555
|b 9
700 1 _ |a Winer, Joseph R
|b 10
700 1 _ |a Teipel, Stefan
|0 P:(DE-2719)2000026
|b 11
700 1 _ |a Weigand, Alexandra J
|b 12
700 1 _ |a Eschenko, Oxana
|b 13
700 1 _ |a Hämmerer, Dorothea
|0 P:(DE-2719)2811927
|b 14
700 1 _ |a Leiman Algranati, Marina
|0 P:(DE-2719)9001927
|b 15
700 1 _ |a Counts, Scott E
|b 16
700 1 _ |a Shine, James M
|b 17
700 1 _ |a Robertson, Ian H
|b 18
700 1 _ |a Levey, Allan I
|b 19
700 1 _ |a Lancini, Elisa
|0 P:(DE-2719)9002565
|b 20
|u dzne
700 1 _ |a Son, Gowoon
|b 21
700 1 _ |a Schneider, Chrisoph
|b 22
700 1 _ |a Egroo, Maxime Van
|b 23
700 1 _ |a Liguori, Claudio
|b 24
700 1 _ |a Wang, Qin
|0 P:(DE-HGF)0
|b 25
700 1 _ |a Vazey, Elena M
|b 26
700 1 _ |a Rodriguez-Porcel, Federico
|b 27
700 1 _ |a Haag, Lena
|0 P:(DE-2719)9002566
|b 28
|u dzne
700 1 _ |a Bondi, Mark W
|b 29
700 1 _ |a Vanneste, Sven
|b 30
700 1 _ |a Freeze, Whitney M
|b 31
700 1 _ |a Yi, Yeo-Jin
|0 P:(DE-2719)9002257
|b 32
700 1 _ |a Maldinov, Mihovil
|b 33
700 1 _ |a Gatchel, Jennifer
|b 34
700 1 _ |a Satpati, Abhijit
|b 35
700 1 _ |a Babiloni, Claudio
|b 36
700 1 _ |a Kremen, William S
|b 37
700 1 _ |a Howard, Robert
|b 38
700 1 _ |a Jacobs, Heidi I L
|b 39
700 1 _ |a Grinberg, Lea T
|b 40
773 _ _ |a 10.1002/alz.12937
|g p. alz.12937
|0 PERI:(DE-600)2201940-6
|n 5
|p 2182-2196
|t Alzheimer's and dementia
|v 19
|y 2023
|x 1552-5260
856 4 _ |u https://pub.dzne.de/record/194973/files/DZNE-2023-00160%20SUP.doc
856 4 _ |u https://pub.dzne.de/record/194973/files/DZNE-2023-00160%20SUP.docx
856 4 _ |u https://pub.dzne.de/record/194973/files/DZNE-2023-00160%20SUP.odt
856 4 _ |u https://pub.dzne.de/record/194973/files/DZNE-2023-00160%20SUP.pdf
856 4 _ |u https://pub.dzne.de/record/194973/files/DZNE-2023-00160.pdf
|y OpenAccess
856 4 _ |u https://pub.dzne.de/record/194973/files/DZNE-2023-00160.pdf?subformat=pdfa
|x pdfa
|y OpenAccess
909 C O |o oai:pub.dzne.de:194973
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 8
|6 P:(DE-2719)9002575
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 9
|6 P:(DE-2719)2810555
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 11
|6 P:(DE-2719)2000026
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 14
|6 P:(DE-2719)2811927
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 15
|6 P:(DE-2719)9001927
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 20
|6 P:(DE-2719)9002565
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 28
|6 P:(DE-2719)9002566
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 32
|6 P:(DE-2719)9002257
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2023
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2022-11-11
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2022-11-11
|w ger
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2022-11-11
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ALZHEIMERS DEMENT : 2022
|d 2023-10-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-10-25
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b ALZHEIMERS DEMENT : 2022
|d 2023-10-25
920 1 _ |0 I:(DE-2719)5000006
|k AG Düzel
|l Clinical Neurophysiology and Memory
|x 0
920 1 _ |0 I:(DE-2719)1510100
|k AG Teipel
|l Clinical Dementia Research (Rostock /Greifswald)
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)5000006
980 _ _ |a I:(DE-2719)1510100
980 _ _ |a UNRESTRICTED
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21